Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.

Abstract

Liposomal annamycin (L-AN) has shown antitumor activity in preclinical studies. It may selectively target tumors and bypass MDR-1 resistance. A total of 13 women with doxorubicin-resistant breast cancer were treated on this phase II study. The median number of prior chemotherapy regimens was two, and six patients had two or more organ sites of involvement. L-AN was administered at 190-250 mg/m(2) as an i.v. infusion over 1-2 h every 3 weeks. No responses were observed. Of the 13 patients, 12 had clear deterioration and new tumor growth after one or two courses. The 13th patient had prolonged grade 2 thrombocytopenia after one course, and was taken off study when the lung metastases increased 62 days after treatment. L-AN at this dose and on this schedule had no detectable antitumor activity in patients with doxorubicin-resistant metastatic breast cancer.

• Authors: Daniel J Booser, Francisco J Esteva, Edgardo Rivera, Vicente Valero, Laura Esparza-Guerra, Waldemar Priebe, Gabriel N Hortobagyi
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 50 Issue 1 Pg. 6-8 (Jul 2002) ISSN: 0344-5704 [Print] Germany
• PMID: 12111105 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibiotics, Antineoplastic
• Drug Carriers
• Liposomes
• Doxorubicin
• annamycin

Topics

• Adult
• Aged
• Antibiotics, Antineoplastic (adverse effects, therapeutic use)
• Breast Neoplasms (drug therapy, pathology)
• Doxorubicin (adverse effects, analogs & derivatives, therapeutic use)
• Drug Carriers
• Drug Resistance, Neoplasm
• Female
• Humans
• Infusions, Intravenous
• Liposomes
• Lung Neoplasms (drug therapy, secondary)
• Maximum Tolerated Dose
• Middle Aged